Chao-Yue Cui
Overview
Explore the profile of Chao-Yue Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen D, Cheng K, Wan L, Cui C, Li G, Zhao D, et al.
Imeta
. 2024 Jun;
3(1):e158.
PMID: 38868515
Antimicrobial resistance (AMR) is a major threat to global public health, and antibiotic resistance genes (ARGs) are widely distributed across humans, animals, and environment. Farming environments are emerging as a...
2.
Chen C, Huang P, Cui C, He Q, Sun J, Liu Y, et al.
Front Microbiol
. 2022 Sep;
13:974432.
PMID: 36081799
The rapid dissemination of plasmid-mediated (X) genes in species has compromised the clinical effectiveness of tigecycline, one of the last-resort antibiotics. However, the classification strategy and homology group of (X)-positive...
3.
Zhang R, Sun J, Sun R, Wang M, Cui C, Fang L, et al.
Microbiol Spectr
. 2022 Apr;
10(3):e0113122.
PMID: 35476541
No abstract available.
4.
Cui C, Chen Q, He Q, Chen C, Zhang R, Feng Y, et al.
WIREs Mech Dis
. 2022 Jan;
14(1):e1538.
PMID: 35023325
Tetracycline and its derivative tigecycline are clinical options against Gram-negative bacterial infections. The emergence of mobile Tet(X) enzymes that destruct tetracycline-type antibiotics is posing a big challenge to antibacterial therapy...
5.
Zhang R, Sun J, Sun R, Wang M, Cui C, Fang L, et al.
Microbiol Spectr
. 2021 Dec;
9(3):e0116421.
PMID: 34935428
The emergence of (X) genes has compromised the clinical use of the last-line antibiotic tigecycline. We identified 322 (1.21%) (X) positive samples from 12,829 human microbiome samples distributed in four...
6.
Cui C, Li X, Chen C, Wu X, He Q, Jia Q, et al.
Sci Total Environ
. 2021 Oct;
806(Pt 2):150687.
PMID: 34597551
The emergence of novel plasmid-mediated high-level tigecycline resistance genes tet(X) in the Enterobacteriaceae has increased public health risk for treating severe bacterial infections. Despite growing reports of tet(X)-positive isolates detected...
7.
Yu Y, Cui C, Kuang X, Chen C, Wang M, Liao X, et al.
Front Microbiol
. 2021 Sep;
12:716393.
PMID: 34497596
Objectives: Carbapenems, colistin, and tigecycline are critically important antibiotics in clinics. After the global appearance of and mediating the resistance to carbapenems and colistin, respectively, tigecycline becomes the last-resort drug...
8.
He Q, Cui C, Zhang X, Lin Z, Jia Q, Li C, et al.
Sci Total Environ
. 2021 Aug;
799:149360.
PMID: 34365265
Tetracycline antibiotics (TCs) are massively produced and consumed in various industries resulting in large quantities of residuals in the environment. In this study, to achieve safe and efficient removal of...
9.
Cui C, He Q, Jia Q, Li C, Chen C, Wu X, et al.
mSystems
. 2021 May;
6(3).
PMID: 34006624
The emergence of the plasmid-mediated high-level tigecycline resistance mechanism Tet(X) threatens the role of tigecycline as the "last-resort" antibiotic in the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. Compared...
10.
Chen C, Cui C, Wu X, Fang L, He Q, He B, et al.
Vet Microbiol
. 2020 Dec;
253:108954.
PMID: 33373881
The recent emergence of plasmid-mediated tigecycline resistance gene tet(X) has challenged the clinical effectiveness of tigecycline as a last-resort treatment option. During 2017-2018, 336 fecal samples from sick ducks, pigs,...